evipedia.ai ← Back

trans-Resveratrol for Health & Longevity

Evidence Review created on 08/12/2026 using AI4L / Opus 5

Also known as: Resveratrol, trans-3,5,4’-trihydroxystilbene, Japanese knotweed extract, Polygonum cuspidatum extract, RSV

Motivation

trans-Resveratrol is the naturally occurring form of a plant compound found in the skins of red grapes, in red wine, in peanuts, and in the roots of Japanese knotweed. Plants make more of it when injured or infected. Interest in it as a health compound began when laboratory work suggested it might switch on some of the same repair and energy-saving machinery that a very low-calorie diet does.

It became widely known after reports that it lengthened the lives of yeast, worms, flies and short-lived fish, and improved the health of overfed mice. A large supplement market grew up around those findings. Human results have been far less tidy: some trials report better blood vessel function, denser bone and steadier blood sugar, while others of similar size and quality find nothing, and a few report unwanted changes.

This review examines what controlled human research shows about trans-resveratrol: where effects are consistent, where they conflict, how much of a swallowed dose actually reaches the body intact, which doses and forms have been tested, and what risks and interactions have been recorded.

Benefits - Risks - Protocol - Conclusion

High-level treatments of trans-resveratrol from expert practitioners and longevity-focused publications, spanning both supportive and sceptical readings of the evidence.

Note on coverage: Chris Kresser’s platform was searched directly. Resveratrol appears there only inside broader pieces — the Revolution Health Radio interview with David Sinclair treats it alongside NMN and metformin, and shorter mentions sit in articles on plant compounds and on wine — so no dedicated treatment competed for the five slots above.

Grokipedia

  • Resveratrol

    Useful for chemistry, plant sources, isomer differences and metabolite naming, with more detail on the sulfate and glucuronide conjugates than most consumer-facing summaries provide.

Examine

  • Resveratrol

    Grades outcomes across 27 conditions from roughly 22,000 participants in eight trials and 22 pooled analyses, and states plainly that no human lifespan evidence exists.

ConsumerLab

Systematic Reviews

The systematic reviews and pooled analyses below cover both the claimed benefits of trans-resveratrol and its safety profile.

Mechanism of Action

trans-Resveratrol is a stilbene, a small two-ring plant compound that acts weakly on many targets rather than strongly on one. The original proposal was direct activation of SIRT1 (sirtuin 1, an enzyme that switches other proteins on and off when nutrients are scarce), mimicking calorie restriction. A competing explanation holds the founding assay was an artifact: Pacholec et al. found activation only with a fluorescently tagged peptide, not with native substrates.

The prevailing indirect account is that trans-resveratrol blocks phosphodiesterases (enzymes that break down cellular messenger molecules), raising cyclic messenger and calcium signalling, which activates AMPK (AMP-activated protein kinase, the cell’s low-fuel sensor) and lifts NAD+ (nicotinamide adenine dinucleotide, the coenzyme sirtuins require), so SIRT1 is engaged indirectly. It also inhibits cyclooxygenase-2 (an inflammation-generating enzyme), stimulates nitric oxide production in artery linings, and binds oestrogen receptors weakly in both directions.

Pharmacologically, absorption is high but bioavailability very low: gut and liver enzymes convert most of a dose to sulfate and glucuronide conjugates within minutes, so the parent compound rarely exceeds low nanogram concentrations. Distribution is wide but shallow: conjugates concentrate in gut, liver and kidney, reach cerebrospinal fluid only at low levels, and form an intracellular sulfate pool regenerating the parent compound. Half-life is 1–3 hours single-dose and 2–5 hours with repeated dosing (Almeida et al.). Conjugation runs through UGT1A1 and UGT1A9 (sugar-attaching enzymes) and SULT1A1 (a sulfate-attaching enzyme). At one gram daily it inhibits CYP3A4, CYP2D6 and CYP2C9 and induces CYP1A2, the main drug-clearing liver enzymes (Chow et al.).

Historical Context & Evolution

trans-Resveratrol was first isolated around 1940 from the roots of white hellebore (Veratrum grandiflorum) and later found in Polygonum cuspidatum (Japanese knotweed), a root long used in Japanese and Chinese herbal practice for circulatory and inflammatory complaints. It had no health-optimisation profile until 1992, when it was proposed as a candidate explanation for the “French paradox”, the comparatively low coronary heart disease rate observed in wine-drinking populations eating saturated-fat-rich diets. A 1997 report by Jang et al. of cancer-preventive activity across initiation, promotion and progression broadened scientific interest.

The pivot to longevity came in 2003, when Howitz et al. reported that resveratrol stimulated the yeast sirtuin and extended yeast lifespan by about 70%. Baur et al. then showed that overfed middle-aged mice given resveratrol survived longer, gained insulin sensitivity and mitochondria, and opposed 144 of 153 diet-altered gene pathways. Those findings stand and have been reproduced in worms, flies and short-lived fish; what is contested is the mechanism and whether it transfers to well-fed mammals.

The 2010 finding that the activation depended on a labelled substrate reframed the mechanism rather than the animal results. A 2012 university misconduct finding against a separate resveratrol laboratory concerned that group’s cardiac papers, not the yeast or mouse work above, which has not been retracted. Commercially, Sirtris was acquired by GlaxoSmithKline in 2008 for roughly $720 million and its micronised formulation was discontinued in 2010; the field has since shifted from lifespan claims to biomarker endpoints.

Expected Benefits

High 🟩 🟩 🟩

Improved Endothelial Function

The artery lining relaxes more readily, most likely through increased nitric oxide production and reduced adhesion-molecule expression on the vessel wall. The evidence basis is a meta-analysis of 21 treatment arms from 17 randomized trials, with a consistent direction across doses and populations. The effect is on a surrogate measurement rather than on cardiovascular events, and effects were largest in participants who already had vascular disease, so the size of the benefit in a metabolically healthy, well-trained person is likely to be smaller.

Magnitude: Flow-mediated dilation (a measure of how well an artery widens when blood flow increases) rose by 1.43 percentage points (95% confidence interval 0.98 to 1.88), and the adhesion protein ICAM-1 fell by 7.09 ng/mL (Mohammadipoor et al. 2022).

Medium 🟩 🟩

Better Glycemic Control in Insulin-Resistant States ⚠️ Conflicted

Pooled analyses of randomized trials report lower long-term blood sugar and better insulin sensitivity, plausibly via the low-fuel sensor pathway described above. The conflict is stark: pooled data are favourable, but the two best-powered individual trials are null. Bo et al. 2016 randomized 192 people with type 2 diabetes for six months and found no change in weight, blood pressure, fasting glucose, long-term glucose or insulin. The Cochrane review found only three tiny trials. Benefit appears confined to people who start with disturbed glucose handling.

Magnitude: Pooled standardised mean difference for HbA1c (glycated haemoglobin, a three-month average of blood sugar) was −0.48 (95% confidence interval −0.69 to −0.27) across 25 trials in 1,171 participants (Zhou et al. 2022); the largest single trial found no effect.

Increased Bone Mineral Density

Bone formation markers rise and spinal bone density increases, apparently by stimulating mineralisation rather than by suppressing bone breakdown. Two independent randomized trials support this in different populations: middle-aged obese men over 16 weeks, and postmenopausal women over 12 months (Wong et al. 2020). This is one of the few domains where a dose-response relationship was demonstrated and where the effect was seen on an imaging endpoint rather than only on a blood marker. Hip density did not change consistently.

Magnitude: At 1,000 mg daily, lumbar spine trabecular bone density rose 2.6 ± 1.3% versus placebo and bone alkaline phosphatase (an enzyme released by bone-building cells) rose about 15–16% (Ornstrup et al. 2014).

Reduced Markers of Systemic Inflammation ⚠️ Conflicted

Circulating inflammatory signals fall in many trials, consistent with cyclooxygenase-2 inhibition and reduced adhesion-molecule expression. The broadest synthesis of the clinical literature concluded that resveratrol “consistently reduces inflammatory markers”. Against that, the most rigorously phenotyped trial in metabolic syndrome found no change in high-sensitivity C-reactive protein (a general inflammation marker), interleukin-6, or inflammatory gene expression in fat and muscle biopsies. The discrepancy tracks with baseline inflammation: reductions cluster in populations that started with elevated markers.

Magnitude: Direction is consistently downward in pooled trial data, largest where baseline markers are elevated; the systematic review reporting the effect gives no single pooled outcome figure across indications (Brown et al. 2024).

Low 🟩

Lower Systolic Blood Pressure at Higher Doses ⚠️ Conflicted

A subgroup of pooled randomized trials found a large drop in the upper blood pressure number only at doses of 150 mg daily or more. The base is six small trials, the dose relationship was not confirmed statistically, and later better-powered trials found no change at all.

Magnitude: −11.90 mmHg systolic (95% confidence interval −20.99 to −2.81) at ≥150 mg daily in a six-trial subgroup of 247 participants (Liu et al. 2015); null in later individual trials.

Improved Blood Lipid Profile ⚠️ Conflicted

Pooled trial data show modest falls in total and low-density lipoprotein cholesterol, the fraction that drives artery plaque. This conflicts with individual trials in which cholesterol rose at high dose, and with evidence that it abolishes exercise-induced lipid gains. Direction appears dose- and context-dependent.

Magnitude: Pooled standardised mean difference −0.42 (95% confidence interval −0.57 to −0.27) for low-density lipoprotein cholesterol (Zhou et al. 2022); opposite direction at 1,000 mg daily in metabolic syndrome.

Cerebrovascular Responsiveness and Cognition ⚠️ Conflicted

A 14-week randomized trial in postmenopausal women found better blood flow responsiveness in brain vessels and improved overall cognitive performance. Eleven separate pooled human analyses found no significant cognitive, mood or brain-volume effect, in sharp contrast to consistently positive rodent data. Any real effect is small.

Magnitude: Direction favourable for cerebrovascular responsiveness in a single 14-week trial (Evans et al. 2017); pooled human analyses report no significant cognitive effect, so no reliable outcome figure exists.

Reduced Musculoskeletal Pain After Menopause

A 2025 pooled analysis of ten randomized trials in 928 postmenopausal women found lower pain scores, while cognition, mood, metabolic measures, blood pressure, sleep and quality of life were unchanged. The finding rests on differing pain instruments across a small trial set.

Magnitude: Pain visual analogue score −7.59 points (95% confidence interval −12.91 to −2.26) (Wu et al. 2025).

Small Reduction in Waist Circumference ⚠️ Conflicted

Pooled randomized data show a modest reduction in abdominal girth without reliable change in total body weight, consistent with a metabolic rather than an appetite effect. Variation between trials was very high, and the larger individual trials found no change in body composition.

Magnitude: Pooled standardised mean difference −0.36 (95% confidence interval −0.59 to −0.14) for waist circumference (Zhou et al. 2022).

Speculative 🟨

Slowed Biological Aging

Lifespan extension is documented in yeast, worms, flies, fish and overfed mice. No human trial has measured lifespan or a validated aging clock, so the basis is animal and mechanistic only.

Cancer Chemoprevention

Repeated high doses lowered circulating insulin-like growth factor 1 in healthy volunteers, a plausible chemoprevention route. No controlled human trial has shown reduced cancer incidence, so the basis remains mechanistic (Brown et al. 2010).

Benefit-Modifying Factors

  • Conjugating enzyme variants: SULT1A1 and UGT1A1 variants (which govern how fast the compound is sulfated or sugar-tagged) alter how much parent compound survives first-pass metabolism, plausibly explaining the very wide between-person variability seen in pharmacokinetic studies.

  • Baseline metabolic and inflammatory status: Benefit clusters in people who start with elevated blood sugar, cholesterol or inflammation markers. In metabolically healthy people, Yoshino et al. 2012 found no improvement in insulin sensitivity or mitochondrial function.

  • Sex and hormonal status: Bone, pain and cerebrovascular signals come predominantly from postmenopausal women, where weak oestrogen-receptor binding may matter. The unfavourable cholesterol response was observed in middle-aged men at high dose.

  • Pre-existing conditions: Type 2 diabetes, metabolic syndrome and obesity are the settings with the most favourable data. Fatty liver disease is an exception, where an 8-week trial showed no benefit and rising liver enzymes.

  • Age and training status: Older adults show benefit in mobility and muscle function when the compound is combined with exercise in some trials, yet in trained-effort settings it has blunted training adaptations, making the net age effect dependent on how hard the person trains.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Dose-Dependent Gastrointestinal Symptoms

Nausea, diarrhoea, flatulence and abdominal pain appear reliably once daily doses reach the multi-gram range, most likely from unabsorbed compound reaching the colon. In a 29-day dose-escalation study in 40 healthy volunteers, 2.5 g and 5 g daily produced mild to moderate gastrointestinal symptoms, while 0.5 g and 1 g did not. The Alzheimer trial, which escalated to 1 g twice daily, listed nausea, diarrhoea and weight loss as its most common adverse events. Symptoms are reversible on dose reduction.

Magnitude: Mild to moderate symptoms are common at 2.5–5 g daily and uncommon at or below 1 g daily; the dose-escalation study reports tolerability by dose level without an incidence figure (Brown et al. 2010).

Medium 🟥 🟥

Blunting of Exercise Training Adaptations ⚠️ Conflicted

Because part of exercise’s benefit is mediated by transient oxidative and inflammatory signalling, an antioxidant taken alongside training may suppress the adaptive response. In a randomized trial of 27 previously inactive men aged around 65 doing eight weeks of high-intensity training, resveratrol suppressed gains in maximal oxygen uptake, blocked the fall in mean arterial pressure, and abolished the training-induced improvements in cholesterol and triglycerides. Some later trials combining the compound with exercise in frailer older adults report the opposite, so the effect may depend on training intensity.

Magnitude: The placebo group’s increase in maximal oxygen uptake was 45% greater than the resveratrol group’s, and only placebo showed a mean arterial pressure fall of 4.8 ± 1.7 mmHg (Gliemann et al. 2013).

Raised Cholesterol at High Doses

In a 16-week randomized trial of 74 middle-aged men with metabolic syndrome, 1,000 mg daily significantly increased total cholesterol, low-density lipoprotein cholesterol and fructosamine (a two-to-three-week average of blood sugar) compared with placebo, with no offsetting benefit on inflammation, blood pressure or body composition. A separate six-month trial also saw small rises in total cholesterol and triglycerides at 500 mg daily. This is the single most consistent adverse laboratory signal in the high-dose literature.

Magnitude: Significant increases in total cholesterol (p < 0.002) and low-density lipoprotein cholesterol (p < 0.006) at 1,000 mg daily for 16 weeks; the trial reports the direction and significance but no percentage change (Kjær et al. 2017).

Altered Clearance of Prescription Drugs

At one gram daily for four weeks in 42 healthy volunteers, resveratrol inhibited the activity of CYP3A4, CYP2D6 and CYP2C9 and induced CYP1A2. Because these liver enzymes clear a large share of prescription medicines, the practical consequence is unpredictable rises in blood levels of drugs cleared by the inhibited enzymes and falls in those cleared by the induced one. The study authors explicitly warned that pharmacological doses could cause adverse drug reactions or altered drug efficacy.

Magnitude: Phenotypic indices of three major clearing enzymes were inhibited and one induced at 1 g daily; the study reports direction and significance without a single fold-change figure (Chow et al. 2010).

Rising Liver Enzymes at Very High Doses

In an 8-week randomized trial of 20 overweight men with fatty liver disease taking 3,000 mg daily, alanine and aspartate aminotransferases (enzymes released when liver cells are stressed) rose significantly versus placebo through week 6, while insulin resistance, liver fat and abdominal fat were unchanged. The authors interpreted this as increased hepatic stress rather than benefit, in a population in which the compound is often promoted.

Magnitude: Significant increases in both liver enzymes versus placebo at 3,000 mg daily over eight weeks; the trial reports the direction and significance without a pooled effect size (Chachay et al. 2014).

Low 🟥

Increased Bleeding Tendency with Antithrombotic Therapy

The compound inhibits platelet clumping in laboratory work and inhibits CYP2C9, the enzyme clearing warfarin. Combined with an anticoagulant or antiplatelet drug, the plausible consequence is easier bruising and prolonged bleeding. No trial has measured bleeding events, so this rests on mechanism plus testing-body caution.

Magnitude: Direction is toward reduced platelet aggregation and increased bleeding tendency when combined with antithrombotic drugs; no clinical trial reports a bleeding-event rate.

Accelerated Brain Volume Loss

In a 52-week randomized trial of 119 people with mild to moderate Alzheimer disease, brain volume loss on imaging was greater with resveratrol than placebo. Whether this reflects harm, reduced swelling, or an amyloid-clearance artifact is unresolved, and it has not been examined in healthy adults.

Magnitude: Greater brain volume loss versus placebo over 52 weeks at up to 2 g daily; the trial reports the direction without an interpretable volume figure (Turner et al. 2015).

Renal Adverse Events with High-Dose Micronised Formulations

A phase 2 trial of micronised resveratrol at 5 g daily with bortezomib in relapsed multiple myeloma was terminated early after kidney injury, including cast nephropathy (protein casts blocking kidney tubules). Kidney failure is common in that disease, so attribution is uncertain.

Magnitude: Early trial termination for renal toxicity at 5 g daily of a micronised formulation in a cancer population; the report gives no adverse-event rate (Popat et al. 2013).

Speculative 🟨

Stimulation of Hormone-Sensitive Tissue

The compound binds oestrogen receptors and can act as a weak mimic or a blocker depending on tissue. No controlled human data exist in hormone-sensitive cancer, so this caution is mechanistic only.

Impaired Iron Status

Isolated user reports of mild iron-deficiency anaemia have been logged by an independent testing body, and polyphenols bind non-heme iron in the gut. No controlled data exist, so the basis is isolated reports.

Risk-Modifying Factors

  • Drug-metabolising enzyme variants: People who are already slow metabolisers at CYP2D6 or CYP2C9 (enzymes clearing many antidepressants, beta-blockers and warfarin) face compounded exposure when resveratrol inhibits the same enzymes, widening the interaction risk.

  • Baseline liver enzymes and cholesterol: Elevated starting transaminases or low-density lipoprotein cholesterol identify the two laboratory values most likely to worsen, since both the liver-stress and cholesterol-raising signals appeared at high dose in already-dysmetabolic groups.

  • Sex differences: The cholesterol rise was documented in middle-aged men; the oestrogen-receptor caution applies chiefly to women with hormone-sensitive conditions. Sex-specific adverse-event rates have not otherwise been reported separately in the trial literature.

  • Pre-existing conditions: Fatty liver disease, bleeding disorders, kidney impairment, hormone-sensitive cancers, and any condition managed with narrow-therapeutic-index drugs each raise the risk profile disproportionately relative to a healthy user.

  • Age and polypharmacy: Older adults tolerated the compound without serious adverse events in the ten-trial safety synthesis, but they also carry the highest medication burden, so the drug-clearance interaction is the dominant age-related risk rather than direct toxicity.

Key Interactions & Contraindications

  • CYP3A4 substrates (simvastatin, atorvastatin, amlodipine, tacrolimus, apixaban, rivaroxaban): Caution. Inhibition raises drug levels, risking muscle injury with statins or bleeding with direct oral anticoagulants. Separate dosing does not reliably help; dose review with the prescriber is the appropriate step.

  • CYP2C9 substrates (warfarin, phenytoin, glipizide, celecoxib): Caution to absolute contraindication with warfarin. Reduced clearance raises anticoagulant effect and bleeding risk. If used at all with warfarin, weekly clotting-time checks until stable are the recognised mitigation.

  • CYP2D6 substrates (metoprolol, carvedilol, tamoxifen, fluoxetine, codeine): Caution. Levels of the parent drug rise, while codeine and tamoxifen may become less effective because they need this enzyme to be activated. Tamoxifen use is a practical contraindication.

  • CYP1A2 substrates (theophylline, clozapine, olanzapine, caffeine): Monitor. Induction speeds clearance and can lower drug levels below the effective range; clozapine and theophylline warrant blood-level checks.

  • Over-the-counter medicines (aspirin, ibuprofen, naproxen, diclofenac): Caution. Additive platelet inhibition raises bruising and gastrointestinal bleeding risk. Avoid routine combination with daily low-dose aspirin without medical review.

  • Supplements with additive antiplatelet effects (fish oil, ginkgo, garlic extract, high-dose vitamin E, nattokinase, curcumin): Caution. Additive bleeding tendency, especially before surgery or dental procedures. Stop all of them together 7–14 days pre-operatively.

  • Supplements with additive metabolic or blood-pressure effects (berberine, quercetin, pterostilbene, beetroot nitrate): Monitor. Additive glucose or blood-pressure lowering can produce hypoglycaemia (blood sugar dropping too low) or light-headedness when stacked with medication.

  • Structured exercise training: Caution. This is the interaction most relevant to this audience: concurrent high-intensity training plus resveratrol blunted fitness, blood pressure and lipid gains. Timing separation from training sessions is the only available mitigation.

Populations who should avoid trans-Resveratrol:

  • Women with oestrogen-sensitive cancers or a history of them, including breast and endometrial cancer, and women taking tamoxifen
  • Pregnant and breastfeeding women, and children, for whom no safe upper intake has been established
  • People with an inherited or acquired bleeding disorder, or on full-dose anticoagulation, or within 14 days of scheduled surgery
  • People with active liver disease or transaminases above three times the upper limit of normal
  • People with moderate to severe kidney impairment (estimated glomerular filtration rate below 45 mL/min/1.73 m², a measure of kidney filtering capacity), particularly with absorption-enhanced formulations

Risk Mitigation Strategies

  • Cap the daily dose at 500 mg: Gastrointestinal symptoms, the cholesterol rise and the liver-enzyme rise all clustered at 1,000–3,000 mg daily. Staying at or below 500 mg avoids the dose range where each of those signals appeared.

  • Start at 100–150 mg and titrate over four weeks: Beginning low and increasing every one to two weeks identifies gastrointestinal intolerance early and avoids the abrupt multi-gram exposures associated with nausea and diarrhoea.

  • Check a lipid panel and liver enzymes at 12 weeks: This directly detects the two documented laboratory harms, raised low-density lipoprotein cholesterol and rising transaminases, while they are still reversible on discontinuation.

  • Separate dosing from hard training by at least six hours: Because the compound’s half-life is 1–5 hours, dosing away from high-intensity sessions limits antioxidant exposure during the adaptive window that resveratrol blunted in aged men.

  • Review every prescription medicine with a pharmacist first: This addresses the drug-clearance risk, which is the most probable serious harm; particular attention to warfarin, statins, tamoxifen, clozapine and direct oral anticoagulants.

  • Stop 14 days before any surgery or dental procedure: This mitigates additive bleeding risk from platelet inhibition, allowing several half-lives plus platelet turnover before the procedure.

Therapeutic Protocol

  • Standard supplement protocol: 150–500 mg of trans-resveratrol once daily with a fat-containing meal, taken continuously. This range covers most positive trials, including the 150 mg bone and metabolic arms and the 250 mg cardiovascular work.

  • High-dose research protocol: 1,000 mg daily was used in the bone-density and metabolic syndrome trials. It produced the largest bone signal but also the cholesterol rise, so the trade-off is explicit rather than free.

  • Competing approach, food-first: Some practitioners argue for whole grape, berry and red wine polyphenol intake instead of isolated compound, on the grounds that isolated high-dose antioxidants may suppress useful stress signalling.

  • Competing approach, analogue substitution: Others favour pterostilbene, a methylated relative with higher oral bioavailability and a longer half-life, accepting a much thinner human trial base in exchange for better absorption.

  • Popularisers of each approach: The high-dose longevity protocol traces to David Sinclair’s Harvard laboratory and the Sirtris programme; the sceptical, food-first reading is argued in detail by Peter Attia’s team and by Andrew Huberman.

  • Best time of day: Morning. Bioavailability was higher after morning administration in the multiple-dose pharmacokinetic study, which also found circadian variation in absorption.

  • Half-life: 1–3 hours after a single dose and 2–5 hours with repeated dosing; conjugated metabolites persist far longer and reach concentrations up to twentyfold higher than the parent compound.

  • Single versus split dosing: Trials have used both. The short half-life argues for splitting, but the intracellular sulfate reservoir means once-daily dosing was sufficient in the successful bone and vascular trials.

  • Genetic considerations: SULT1A1 and UGT1A1 variants govern first-pass conjugation and plausibly drive the greater-than-40% between-person variability in blood levels; CYP2C9 and CYP2D6 variants matter chiefly for interactions rather than for efficacy.

  • Sex-based considerations: Positive bone, pain and cerebrovascular trials used postmenopausal women at 75 mg twice daily or 150 mg daily. The unfavourable cholesterol response occurred in men at 1,000 mg daily.

  • Age considerations: Older adults tolerate the compound well, but those training at high intensity should weigh the blunting evidence; those with mobility limitation may be the subgroup where combination with exercise helped.

  • Baseline biomarker considerations: Response tracks starting values. Normal glucose, normal inflammation markers and normal bone density predict little measurable change, as seen in metabolically healthy participants.

  • Pre-existing conditions: Metabolic syndrome, type 2 diabetes, obesity and postmenopausal bone loss are the settings with supportive data; fatty liver disease is the setting with counter-evidence.

Discontinuation & Cycling

  • Intended duration: Framed as an indefinite daily supplement in longevity practice, but no trial has run beyond 24 months, so long-term use is an extrapolation from short trials rather than a tested protocol.

  • Withdrawal effects: None reported. No trial has documented rebound, dependence or symptom recurrence on stopping, and the short half-life makes physiological withdrawal implausible.

  • Tapering: Not required. The compound can be stopped abruptly; abrupt cessation is in fact the appropriate response to rising liver enzymes or cholesterol on follow-up testing.

  • Cycling for efficacy: No efficacy-based rationale exists, as tolerance has not been demonstrated. A pragmatic case exists for pausing during high-intensity training blocks, given the blunting evidence.

  • Planned stopping points: Discontinue 14 days before surgery, on starting any interacting prescription drug, and if a 12-week lipid or liver check moves in the wrong direction.

Sourcing and Quality

  • Label accuracy is the dominant problem: Independent testing of thirty resveratrol products sold on a large online marketplace found most contained under ten percent of the claimed amount, making third-party verification the single most important purchase criterion.

  • Specify the trans isomer: Only trans-resveratrol is the researched form; the cis isomer forms on exposure to light and heat and is not the compound studied. Labels should state trans-resveratrol milligrams, not “resveratrol complex”.

  • Prefer Japanese knotweed extract standardised to 98%: Most supplement material comes from Polygonum cuspidatum root. A 98% standardised extract minimises emodin, a laxative anthraquinone that co-occurs in the root.

  • Look for verified third-party testing: Seals from ConsumerLab, NSF International or USP indicate identity and quantity verification. Brands submitted to the published independent comparison included Pure Encapsulations, Solgar, Life Extension (a resveratrol vendor), Longevinex, MRM Nutrition and BulkSupplements.

  • Protect from light and oxygen: trans-Resveratrol isomerises and oxidises on exposure. Opaque containers, sealed blisters and cool storage preserve potency; loose powder in clear jars is the least stable presentation.

  • Beware absorption-enhanced formulations: Micronised and liposomal products deliver substantially more compound at the same label dose, so the effective exposure may land in the dose range where adverse signals appeared.

Practical Considerations

  • Time to effect: Bone formation markers moved within four weeks and bone density within 16 weeks; vascular and glucose measures took 4–24 weeks. Nothing produces a perceptible subjective effect, so testing is the only feedback.

  • Common pitfall, dose inflation: Assuming more is better pushes users into the 1,000–3,000 mg range where cholesterol, liver enzymes and gastrointestinal symptoms worsen without matching benefit gains.

  • Common pitfall, red wine as a source: A glass contains roughly 1–2 mg, hundreds of times less than any studied dose. Drinking wine for resveratrol imports alcohol’s harms for no meaningful compound exposure.

  • Common pitfall, stacking with training: Taking it around high-intensity sessions is the specific pattern associated with blunted fitness and lipid adaptations in the aged-men trial.

  • Regulatory status: Sold as a dietary supplement in the United States and a food supplement in the European Union. It is not approved as a drug anywhere, so manufacturing standards and label claims are not pre-market verified.

  • Cost and accessibility: Inexpensive and freely available without prescription, roughly $0.05–$1.40 per 100 mg of verified trans-resveratrol depending on brand and formulation. Neither cost nor supply is a practical barrier.

  • Funding asymmetry: No insurer or health system pays for it, so no institutional payer has an incentive to favour or suppress it; the asymmetry runs through supplement sellers, who fund and promote favourable research while null trials lack a commercial sponsor.

Interaction with Foundational Habits

  • Sleep: No direct interaction. No trial has reported insomnia, sedation or altered sleep architecture, and a 2025 pooled analysis in postmenopausal women found no effect on sleep disturbance. Morning dosing is preferred for absorption reasons rather than for sleep protection.

  • Nutrition: Direct and potentiating. Absorption improves with dietary fat, so dosing with a meal containing fat is practical. Grapefruit and other CYP3A4-inhibiting foods compound the drug-interaction risk. Co-ingested piperine and quercetin slow conjugation and raise exposure, which is not always desirable.

  • Exercise: Potentially blunting, and the most consequential interaction here. Concurrent high-intensity training in aged men produced smaller fitness gains, no blood pressure fall and no lipid improvement versus placebo. Separating dosing from training sessions by several hours, or pausing during hard training blocks, is the practical response.

  • Stress management: Indirect at most. The proposed route is reduced inflammatory signalling and improved vascular function rather than any direct effect on cortisol, and no controlled trial has measured stress-hormone responses as a primary endpoint in healthy adults.

Monitoring Protocol & Defining Success

Before starting, establish a baseline that covers the specific values this compound has been shown to move in either direction. That means a full lipid panel, liver enzymes, a fasting glucose and insulin pair, high-sensitivity C-reactive protein, and a full iron panel including ferritin. Anyone starting primarily for bone should add a baseline bone density scan, since bone was the domain with the clearest imaging-level effect. Anyone on prescription medication cleared by the liver should record current drug levels or clinical control before the first dose.

For ongoing monitoring, repeat lipids and liver enzymes at 12 weeks, which is when the adverse laboratory signals emerged in trials, then every 6–12 months if stable. Repeat glucose, insulin and inflammation markers at 6 months. Repeat bone density at 12–24 months, matching the interval over which density changes were detected.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL-C < 80 mg/dL Detects the documented cholesterol rise at high dose LDL-C is low-density lipoprotein cholesterol, the plaque-driving fraction. Fast 9–12 hours. Conventional labs flag only above 130 mg/dL, which misses a meaningful rise
ApoB < 80 mg/dL Counts atherogenic particles more reliably than cholesterol mass ApoB is apolipoprotein B, one molecule per plaque-forming particle. Non-fasting acceptable. Conventional labs flag only above 130 mg/dL. Pair with LDL-C to catch discordance
ALT 10–26 U/L (men), 8–22 U/L (women) Detects the hepatic stress signal seen at very high dose ALT is alanine aminotransferase, released when liver cells are stressed. Conventional upper limits near 40–55 U/L are far less sensitive. Avoid intense exercise 48 hours before
AST 10–26 U/L Confirms an ALT rise is hepatic rather than muscular AST is aspartate aminotransferase, also present in muscle. Conventional upper limits near 40 U/L are far less sensitive. Best paired with ALT and creatine kinase
hs-CRP < 0.5 mg/L Tracks the claimed anti-inflammatory benefit hs-CRP is high-sensitivity C-reactive protein, a general inflammation marker. Defer testing 2 weeks after any infection. Conventional cut-off is 3.0 mg/L
HbA1c 4.8–5.3% Tracks the claimed glycemic benefit over three months HbA1c is glycated haemoglobin, an average of blood sugar. Unreliable in anaemia or after blood loss. Conventional threshold is 5.7%
Fasting insulin 2–5 µIU/mL More sensitive than glucose to early insulin resistance Fast 9–12 hours, drawn with glucose to allow HOMA-IR calculation (a simple insulin-resistance index). Most labs report no functional target
Ferritin 50–150 ng/mL (men), 30–120 ng/mL (women) Addresses the isolated reports of iron depletion Ferritin is the iron storage protein. Conventional ranges run to about 400 ng/mL, far above the functional target. It rises with inflammation, so interpret alongside hs-CRP. Pair with transferrin saturation
Bone mineral density T-score above −1.0 The only imaging endpoint with a demonstrated effect Measured by dual-energy X-ray absorptiometry. No blood test substitutes. Same machine and site for repeat scans
INR 2.0–3.0 if on warfarin, otherwise 0.8–1.2 Detects the anticoagulant interaction before bleeding occurs INR is the international normalised ratio, a clotting-time measure. Check weekly for the first month of combined use

Alongside laboratory values, qualitative markers worth tracking are:

  • Digestive comfort, specifically nausea, bloating and stool frequency, since these are the earliest and most common signals of an excessive dose
  • Training response, including whether hard sessions still produce the expected week-to-week progression in strength or endurance
  • Recovery quality between hard sessions, which is the subjective counterpart to the blunting signal
  • Bruising and gum bleeding, as the practical proxy for altered platelet function
  • Energy stability across the day, which is the most accessible reflection of the claimed metabolic effect

Emerging Research

  • Combination formula for Alzheimer prevention: NCT06470061 is a phase 2 trial in 200 participants with cognitive decline or mild cognitive impairment, using a resveratrol-containing combination and measuring change in retinal amyloid-β as the primary endpoint.

  • Heart failure prevention after menopause: NCT06828211 gives 500 mg of trans-resveratrol daily to 80 early-postmenopausal women with high blood pressure and reduced bone density, with heart failure development and long-term safety as co-primary endpoints.

  • Direct ageing-biomarker endpoints: NCT07245979 enrols 120 women with raised body weight and measures p16INK4a gene expression (a senescent-cell marker), telomere length and senescence-associated enzyme activity, rather than the metabolic surrogates used in earlier trials.

  • Testing the exercise-blunting question directly: NCT06585865 combines resveratrol with strength training in 36 participants with sarcopenia (age-related muscle loss), measuring muscle torque, fatigability, strength and lean mass index.

  • Brain-penetrant formulation: NCT07592767, the RESET trial, is a phase 2 safety and dose-finding study of Jotrol in 30 people with Parkinson’s disease, measuring concentrations in both blood and spinal fluid to test whether reformulation overcomes poor bioavailability.

  • Vascular function before cardiac surgery: NCT03762096 enrols 40 people with type 2 diabetes and coronary artery disease for short-interval dosing before surgery, with change in endothelial function as the primary endpoint.

  • Findings that would weaken the case: Replication of the high-dose cholesterol rise reported by Kjær et al. 2017, or of the training blunting reported by Gliemann et al. 2013, would convert two isolated findings into established dose-limiting effects.

  • Findings that would strengthen it: The demonstration by Patel et al. 2013 that sulfate conjugates act as an intracellular reservoir regenerating the parent compound suggests lower, better-tolerated doses could be made effective through formulation rather than dose escalation.

Conclusion

trans-Resveratrol is a plant compound, most supplement material coming from Japanese knotweed root, that became a longevity candidate because it appeared to switch on the cell’s low-fuel machinery. In simple organisms and in overfed mice, that story held up well. In people it has not translated cleanly. The most consistent human signal is better blood vessel widening. Bone density, blood sugar control and inflammation markers move favourably in several pooled analyses and not at all in some of the best-run individual trials. Nothing in the human record shows a change in how long people live.

The core practical problem is that almost none of a swallowed dose survives the gut and liver intact. The doses high enough to compensate are also the doses at which stomach upset appears, cholesterol has risen rather than fallen, liver enzymes have climbed, and drug-clearing pathways have been disturbed. There is also reasonable evidence that it dulls some of the gains from hard training, which matters more for people who train seriously than for a sedentary population.

The evidence base is uneven and its funding is lopsided. Much of the favourable material is produced or promoted by companies that sell the product, while null trials have no commercial sponsor to amplify them, and no insurer or health system has any stake either way. What remains is a cheap, low-certainty compound whose most dependable effects sit on laboratory measurements rather than on health outcomes.

Top - Benefits - Risks - Protocol